John L. Berk, MD
Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, Case Western Reserve University




Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.

Member
Boston University
Pulmonary Center


Assistant Director
Boston University
Amyloidosis Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences




ALN-TTR02-013: ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR amyloidosis)
09/22/2021 - 09/22/2026 (PI)
Alnylam Pharmaceuticals, Inc.


"ALN-TTR02-011, APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Car
09/12/2019 - 09/12/2024 (PI)
Alnylam Pharmaceuticals, Inc.


Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with
03/29/2016 - 03/28/2023 (PI)
Alnylam Pharmaceuticals, Inc.


Protocol ION-682884-CS2: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomy
03/20/2020 - 03/20/2023 (Subcontract PI)
Pharmaceutical Research Associates, Inc. IonisPharmaceuticals


ALN-TTRSC02, HELIOS-B: A Phase 3, Randomized, Double blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cara
12/04/2019 - 12/04/2022 (PI)
Alnylam Pharmaceuticals, Inc.


Protocol # ION-682844-CS3: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
11/15/2019 - 11/15/2022 (Subcontract PI)
Pharmaceutical Research Associates, Inc. IonisPharmaceuticals


HELIOS-A: A Phase 3 Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with hATTR Amyloidosis
03/28/2019 - 11/14/2022 (PI)
Alnylam Pharmaceuticals, Inc.


An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
10/18/2021 - 10/18/2022 (PI)
Eidos Therapeutics, Inc., A BridgeBio Company


"A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy"
10/04/2019 - 10/04/2022 (PI)
Eidos Therapeutics, Inc., A BridgeBio Company


[ION-682884-CS13]: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
09/28/2021 - 09/29/2022 (PI)
Ionis Pharmaceuticals, Inc.


Showing 10 of 32 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2009 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-05 9
2008 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-04 9
2007 THE EFFECT OF DIFLUNISAL ON HEREDITARY AMYLOIDOSIS 2M01RR000533-39-8163 503
2007 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-03 9
2007 Effect of diflunisal on familial amyloidosis 5R01FD002532-03 2
2006 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-02 9
2006 Effect of diflunisal on familial amyloidosis 5R01FD002532-02 2
2005 Effect of diflunisal (IND68092) on familial amyloidosis 1R01NS051306-01 9
2001 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-33-353 503
2000 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-32-353 503
Showing 10 of 15 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022 Jul 23; 1-9. PMID: 35875890
     
  2. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199.View Related Profiles. PMID: 35731907
     
  3. Ando Y, Adams D, Benson MD, Berk JL, Planté-Bordeneuve V, Coelho T, Conceição I, Ericzon BG, Obici L, Rapezzi C, Sekijima Y, Ueda M, Palladini G, Merlini G. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022 Sep; 29(3):143-155. PMID: 35652823
     
  4. Prokaeva T, Joshi T, Klimtchuk ES, Gibson VM, Spencer B, Siddiqi O, Nedelkov D, Hu Y, Berk JL, Cuddy SAM, Dasari S, Chiu A, Choate LA, McPhail ED, Cui H, Chen H, Burks EJ, Sanchorawala V, Connors LH. A novel substitution of proline (P32L) destabilises ß2-microglobulin inducing hereditary systemic amyloidosis. Amyloid. 2022 May 14; 1-8.View Related Profiles. PMID: 35575118; DOI: 10.1080/13506129.2022.2072199;
     
  5. Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid. 2022 Sep; 29(3):184-189.View Related Profiles. PMID: 35253562
     
  6. Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, Kataria S, Lohrmann G, Pipilas AR, Ruberg FL. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022 Jun; 29(2):71-78.View Related Profiles. PMID: 35083944; PMCID: PMC9258521; DOI: 10.1080/13506129.2021.2000388;
     
  7. Benson MD, Berk JL, Dispenzieri A, Damy T, Gillmore JD, Hazenberg BP, Lavatelli F, Picken MM, Röcken C, Schönland S, Ueda M, Westermark P. Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid. 2022 Mar; 29(1):8-13. PMID: 34766859
     
  8. Brannagan TH, Auer-Grumbach M, Berk JL, Briani C, Bril V, Coelho T, Damy T, Dispenzieri A, Drachman BM, Fine N, Gaggin HK, Gertz M, Gillmore JD, Gonzalez E, Hanna M, Hurwitz DR, Khella SL, Maurer MS, Nativi-Nicolau J, Olugemo K, Quintana LF, Rosen AM, Schmidt HH, Shehata J, Waddington-Cruz M, Whelan C, Ruberg FL. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis. 2021 05 06; 16(1):204.View Related Profiles. PMID: 33957949; PMCID: PMC8100737; DOI: 10.1186/s13023-021-01834-0;
     
  9. Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurol Ther. 2021 Jun; 10(1):375-389. PMID: 33638113; PMCID: PMC8140170; DOI: 10.1007/s40120-021-00235-6;
     
  10. Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021 02; 9(2):115-123. PMID: 33309574
     
Showing 10 of 109 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 109 publications over 27 distinct years, with a maximum of 11 publications in 2018

YearPublications
19871
19911
19931
19942
19962
19983
19993
20002
20012
20023
20032
20043
20054
20071
20101
20117
20125
20135
20144
20157
20164
201710
201811
20197
20209
20213
20226

2019 Boston Top Doctors
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

amyloid lung disease
amyloidosis
familial amyloidotic polyneuropathy
pleural effusions
pulmonary fibrosis
tracheobronchial amyloidosis
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Berk's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department